Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer

All eligible patients will be divided into the following two treatment groups nonrandomly.

Image staging group: standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy+brachytherapy).

Surgery staging group: open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (Level of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation will be conducted within 28 days postoperatively.)

Inclusion criteria

• The patients with good compliance, voluntarily signed the informed consent form and participated in the study.
• Histopathology: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma
• Stage (FIGO2018): IB3, IIA2, IIB-IVA;
• ECOG score: 0 ~ 1;
• The expected survival >6 months;
• The result of a pregnancy test (serum or urine) within seven days must be negative for women of childbearing age, who must take contraception during the trial.

Exclusion criteria

• Activity or uncontrol severe infection;
• Liver cirrhosis or other decompensated liver disease;
• A history of immune deficiency, including HIV positive or a congenital immunodeficiency disease;
• Chronic renal insufficiency or renal failure;
• Other malignancies were diagnosed within five years or needed treatments;
• Myocardial infarction, severe arrhythmia and congestive heart failure with grade ≥2 (New York heart association);
• The CT/MRI/PET/CT show that the para-aortic lymph nodes are positive;
• A history of pelvic artery embolization;
• A history of pelvic radiotherapy;
• A history of partial hysterectomy or radical hysterectomy;
• A history of severe allergic reaction to platinum drugs;
• The drugs for the treatment of concomitant disease seriously impaired liver or kidney function, such as tuberculosis;
• Patients who cannot understand the research regimen and refuse to sign the informed consent form;
• Other concomitant diseases or special conditions seriously endanger the patient's health or interfere with the trial.